In the planned interim analysis of patients treated within 3 days after symptom onset (revised intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19Crelated hospitalization or death by day 28 was reduced the nirmatrelvir group than in the placebo group by 6
In the planned interim analysis of patients treated within 3 days after symptom onset (revised intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19Crelated hospitalization or death by day 28 was reduced the nirmatrelvir group than in the placebo group by 6.32 percentage points (95% confidence…